Kiniksa Pharmaceuticals

Biotech & Life Sciences · Lexington, United States · Founded 2015 · IPO 2018

Kiniksa Pharmaceuticals is developing therapies for inflammatory and autoimmune conditions MoreLess

Kiniksa Pharmaceuticals is a biopharmaceutical company focused on developing and delivering therapies for patients with debilitating diseases and unmet medical needs. The company operates in the healthcare and pharmaceutical market, targeting conditions that have limited treatment options. Kiniksa's business model revolves around research and development (R&D) of novel therapies, clinical trials, and subsequent commercialization of approved drugs. Revenue is generated through the sale of these therapies, partnerships, and potential licensing agreements. The company serves patients, healthcare providers, and medical institutions, aiming to improve patient outcomes and quality of life. Kiniksa's approach is patient-centric, emphasizing urgency and integrity in its operations.

Keywords: biopharmaceutical, therapies, debilitating diseases, unmet needs, healthcare, pharmaceutical, R&D, clinical trials, commercialization, patient-centric.

Valuation $5.28B

Revenue $994M

EBITDA $180M

Total funding $100–500M

Power Law Unicorn$1–10B valuation tier Thoroughbred$100M+ revenue

Talent graph

Kiniksa Pharmaceuticals's talent

Book a demo to see the people

Team profiled 19 named & role-tagged

Founders /100 quality score

Key operators 5 quality /100

Potential founders likely future founders

Startup mafia alumni-founded startups

Talent movements in · out past 12 months

Source: Dealroom Talent Intelligence.

Investors

1 investor on Kiniksa Pharmaceuticals's cap table

Sourced from Dealroom's funding and investor records.

Series B+ 1 investor entered at this stage

STRS Ohio

Global footprint

Where Kiniksa Pharmaceuticals has talent and traffic

Workforce by country

4 countries with
team presence

🇺🇸 United States95.8%

🇬🇧 United Kingdom1.9%

🇨🇭 Switzerland1.3%

🇳🇱 Netherlands0.7%

4 countries shown

Web traffic by country

11K monthly visits
across markets

🇺🇸 United States80.9%

🇮🇳 India12.7%

🇮🇹 Italy3.6%

🇪🇬 Egypt1.8%

🇬🇧 United Kingdom0.9%

Top 5 markets shown

Patent intelligence

$24M patent portfolio · 14 active families

Estimated portfolio value

$24M

0.46% of market cap · 22.6× smaller than top peer ChemoCentryx ($550M)

14 active patent families

Where Kiniksa Pharmaceuticals innovates AntagonistAnti antibodyAntiendomysial antibodiesAntigen bindingCD154

Where Kiniksa Pharmaceuticals concentrates vs peers

Each axis is a top-10 topic across Kiniksa Pharmaceuticals and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Kiniksa Pharmaceuticals

An AI-synthesized read of the highest-engagement posts about Kiniksa Pharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Kiniksa Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles